Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
InstantFigure Activewear Compression Racer Back Tank Top AWT020 ...
InstantFigure Activewear Compression Racer Back Tank Top AWT020 : Target
1104 A safe and highly potent PD-1-IL-2 fusion (AWT020) that decouples ...
Frontiers | AWT020: a novel fusion protein harnessing PD-1 blockade and ...
君实生物：创新抗PD-1/IL-2c融合蛋白AWT020获批临床，双靶点设计治疗晚期恶性肿瘤_摩熵医药(原药融云)
AWT-020 Customized Steel Structure Galvanized Welded Steel T Beam Bar ...
君实生物引进的PD-1/IL-2融合蛋白申报临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
君实生物：创新抗PD-1/IL-2c融合蛋白AWT020获批临床，双靶点设计治疗晚期恶性肿瘤_摩熵医药
君实生物：AWT020注射用无菌粉末获临床试验批准_腾讯新闻
First-in-human study of AWT020, a bifunctional anti-PD-1/IL-2 fusion ...
君实生物：AWT020注射用无菌粉末临床试验申请获批_腾讯新闻
AWT-020(AWT-020) - 药物靶点：IL-2R x PD-1_在研适应症：晚期恶性实体瘤，复发性非小细胞肺癌，小细胞肺癌_专利_临床_研发
AWT-020(AWT-020) - 药物靶点：IL-2R x PD-1_在研适应症：晚期癌症，大肠腺癌，黏膜黑色素瘤_专利_临床_研发
Anwita Biosciences Inc.
君实生物的JS213（项目代号AWT020）作为一款PD-1和白细胞介素-2（I_财富号_东方财富网
君实生物双靶点癌症1类新药在中国获批临床
手握三个BD大热，Biotech龙头被低估
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and ...
Full article: Advanced cytokine-based immunotherapies: targeted cis ...
